Clinical Momentum Phase two study of LEVI-04 in knee osteoarthritis is under way; Levicept is actively presenting data at major rheumatology conferences, signaling readiness to partner for later stage trials and commercialization in Europe and beyond.

Partnership Opportunities LEVI-04's first in class mechanism in the neurotrophin pathway offers a distinctive analgesia approach, making licensing or co development deals with pharma attractive to access a novel OA pain target.

Market Access Large OA knee market and established rheumatology networks provide paths for clinician engagement, site recruitment, and KOL support; Levicept’s conference activity can accelerate partner introductions with clinics and researchers.

Financial Collaboration With a lean operating profile and limited revenue, Levicept may favor strategic collaborations that offer milestone driven funding and royalty based upside to reach pivotal trial milestones.

Leadership Europe UK base and experienced leadership position Levicept for regulatory navigation and European partnerships; recent executive appointment plus agile team can accelerate alliance formation with industry players.